Get the Stockscreener App
0.2801
20.88%
-0.0739
Medicus Pharma Ltd stock is traded at $0.2801, with a volume of 2.63M.
It is down -20.88% in the last 24 hours and down -23.01% over the past month.
Medicus Pharma Ltd is a clinical-stage, life sciences, biotech company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets. The company has one operating segment.
See More
Previous Close:
$0.354
Open:
$0.354
24h Volume:
2.63M
Relative Volume:
1.46
Market Cap:
$15.87M
Revenue:
-
Net Income/Loss:
$-28.53M
P/E Ratio:
-0.1573
EPS:
-1.7805
Net Cash Flow:
$-20.10M
1W Performance:
-6.51%
1M Performance:
-23.01%
6M Performance:
-73.58%
1Y Performance:
-85.85%
1-Day Range:
$0.28
$0.362
1-Week Range:
$0.28
$0.368
52-Week Range:
$0.25
$3.05
Medicus Pharma Ltd Stock (MDCX) Company Profile
Name
Medicus Pharma Ltd
Sector
Industry
Phone
610-540-7515
Address
300 CONSHOHOCKEN STATE RD., W. CONSHOHOCKEN
Compare MDCX vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDCX
Medicus Pharma Ltd
|
0.2801 | 18.76M | 0 | -28.53M | -20.10M | -1.7805 |
LLY
Lilly Eli Co
|
1,180.16 | 1.09T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
260.35 | 628.65B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
249.46 | 439.59B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
135.84 | 327.94B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
150.88 | 289.52B | 54.66B | 13.58B | 16.05B | 7.0171 |
Medicus Pharma Ltd Stock (MDCX) Latest News
Top Medicus Pharma (MDCXW) Competitors 2026 - MarketBeat
Market movers: Cisco, Cerebras, Medicus Pharma, Ideal Power... - Proactive financial news
Medicus Pharma advances clinical programs and r... - Pluang
Medicus Pharma advances pipeline during Q2 with key milestones - Yahoo Finance
Medicus Pharma Q2 loss widens to $11.7M, misses EPS estimate - scanx.trade
Medicus Pharma Ltd reports results for the quarter ended June 30Earnings Summary - TradingView
Medicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update - New Castle News
FDA Authorizes Medicus Pharma’s SkinJect Study for Gorlin Syndrome - Stock Titan
Medicus Pharma Ltd. Q2 2026: Net loss $(11.62M), EPS $(0.21) — 10-Q Summary - TradingView
Medicus Pharma (MDCX) widens loss as it raises $32M and adds secured notes - Stock Titan
Enterprise value to EBITDA forward of Medicus Pharma Ltd. – NASDAQ:MDCXW - TradingView
This 1 Stock Has Potential To Change Lives Maneskin (sRqAItrCwb) - Mshale
Price to book forward of Medicus Pharma Ltd. – NASDAQ:MDCX - TradingView
Medicus Pharma Ltd expected to post a loss of 13 cents a shareEarnings Preview - TradingView
Medicus Pharma Ltd. Revenue Breakdown – BOATS:MDCXW - TradingView
Medicus Pharma names Faisal Mehmud CEO of UK subsidiary Antev - Investing.com
Medicus Pharma names Faisal Mehmud CEO of UK subsidiary Antev By Investing.com - Investing.com Nigeria
Medicus Pharma Names Dr. Faisal Mehmud CEO of UK Subsidiary Antev - citybiz
Medicus Pharma Appoints New CEO to Drive Development - Intellectia AI
Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom - The Manila Times
Medicus Pharma CMO to lead Antev's Teverelix clinical programme - Yahoo Finance
Medicus Pharma targets Gorlin Syndrome with SkinJectICYMI - Proactive financial news
Small cap wrap: Medicus Pharma, Tiziana Life Sciences, Namibia Critical Metals... - Proactive financial news
Medicus Pharma receives UAE authorization for Phase 2a endometriosis study of Teverelix - Yahoo! Finance Canada
Medicus Pharma receives UAE approval for endometriosis study By Investing.com - Investing.com Nigeria
Medicus Pharma Secures IND Authorization for Teverelix® Study in UAE - Intellectia AI
Medicus Pharma secures UAE authorization for Teverelix endometriosis study - scanx.trade
Enterprise value to EBITDA forward of Medicus Pharma Ltd. – BOATS:MDCX - TradingView
Medicus Pharma Share PriceMDCX, RNS News, Articles, Quotes, & Charts (NASDAQ:MDCX) - Proactive financial news
Medicus Pharma cleared by FDA for registrational Phase 2b trial in patients with Gorlin Syndrome - Proactive financial news
Small cap wrap: Nextsource Materials, First Phosphate, Medicus Pharma, Nextech3D.ai… - Proactive financial news
FDA clears Medicus Pharma to start Phase 2b tri... - Pluang
Medicus Pharma Ltd (MDCX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Medicus Pharma receives FDA clearance to begin registrational SkinJect study for Gorlin syndrome - Yahoo Finance
Medicus Pharma Receives FDA 'Study May Proceed” Letter for NDA-Enabling Registrational SkinJect® Study in Patients with Gorlin Syndrome - The Manila Times
FDA clears Medicus Pharma to start pivotal SkinJect trial for Gorlin Syndrome skin cancer treatment - Pluang
FDA clears Medicus Pharma Gorlin Syndrome study to proceed - Investing.com
Medicus Pharma Receives FDA “Study May Proceed” Letter for - GlobeNewswire
Medicus Pharma Ltd (MDCX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Medicus Pharma gets FDA go-ahead for SkinJect Gorlin Syndrome Phase 2b trial - scanx.trade
Medicus Pharma Ltd (MDCX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Medicus Pharma Ltd. Revenue Breakdown – NASDAQ:MDCXW - TradingView
Medicus Pharma Ltd (MDCX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
New to The Street to Broadcast Nationwide on Bloomberg Television Tonight at 6:30 PM ET Featuring RHINO Bitcoin, Marina Decisions, Medicus Pharma and Virtuix Holdings - Moomoo
MDCX|Medicus Pharma Ltd|Price:0.370|Chg%:-0.014 - TradingKey
TradingKey - TradingKey
Medicus Pharma Ltd (MDCX) Institutional Confidence - TradingKey
Medicus Pharma Ltd. Revenue Breakdown – NASDAQ:MDCX - TradingView
MDCX|Medicus Pharma Ltd|Price:0.303|Chg%:-0.015 - TradingKey
ICYMI: Medicus Advances Leaner Teverelix Trial After FDA Review - MyChesCo
Medicus Pharma Ltd. (MDCX) Declines 7.39% as Stock Approaches Key Support at $0.36WMA Signal - dars.gov.et
Medicus Pharma Ltd Stock (MDCX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):